DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0175581A1 Haupts Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0175581A1 Haupts Et Al US 2005O175581A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0175581A1 Haupts et al. (43) Pub. Date: Aug. 11, 2005 (54) BIOLOGICAL ENTITIES AND THE (60) Provisional application No. 60/524.960, filed on Nov. PHARMACEUTICAL AND DIAGNOSTIC USE 25, 2003. Provisional application No. 60/543,518, THEREOF filed on Feb. 11, 2004. (76) Inventors: Ulrich Haupts, Koln (DE); Andre (30) Foreign Application Priority Data Koltermann, Koln (DE); Andreas Scheidig, Koln (DE); Christian Jun. 18, 2003 (EP)........................................... O3O13819 Votsmeier, Koln (DE); Ulrich Kettling, Nov. 10, 2003 (EP). ... O3O25851 Koln (DE); Wayne Michael Coco, Nov. 11, 2003 (EP). ... O3O25871 Koln (DE) Feb. 11, 2004 (EP)........................................... O4003058 Correspondence Address: Publication Classification NEEDLE & ROSENBERG, PC. SUTE 1000 (51) Int. Cl." .......................... A61K 38/19; A61K 38/48 999 PEACHTREE STREET (52) U.S. Cl. ........................................ 424/85.1; 424/94.63 ATLANTA, GA 30309-3915 (US) (57) ABSTRACT (21) Appl. No.: 11/021,951 The present invention provides method for the treatment of a disease by applying a medicament comprising a protease (22) Filed: Dec. 22, 2004 with a defined Specificity is capable to hydrolyze specific Related U.S. Application Data peptide bonds within a target Substrate related to Such disease. The proteases with Such a defined specificity can (63) Continuation-in-part of application No. 10/872,198, further be used for related therapeutic or diagnostic pur filed on Jun. 18, 2004. pOSes. Patent Application Publication Aug. 11, 2005 Sheet 1 of 18 US 2005/0175581 A1 Fig. 1 Patent Application Publication Aug. 11, 2005 Sheet 2 of 18 US 2005/0175581 A1 Trypsin IVGGYNCEENSVPYQVSL---NSGYHF- CGGSLINEQWVVSAGHCY - - - - a-Thrombin IVEGSDAEIGMSPWQVMLFRKSPQELL - CGASLISDRWVLTAAHCLLYPP Enteropeptidase WGGSNAKEGAWPWVVGL - - - YYGGRLLCGASLVSSDWLVSAAHCWYGRN t Trypsin - ar. KSRIOVRLGEH---NIEVLEGN-EOFINAAKIIRHPQYD-RKTL a-Thrombin WDKNFTENDLLVRIGKH---SRTRYERNIEKISMLEKIYIHPRYNWRENL Enteropeptidase LE- - - - PSKWTAILGLHMKSNLTSPOTV-PRLID. --EIVINPHYN-RRRK - - - - - Trypsin NNDIMLIKLSSRAVINARVSTISLPTA- - - - PPAT- - - - - GTKCISGWG a-Thrombin DRDIALMKLKKPVAFSDYIHPVCLPDR- - - - ETAASLLOAGYKGRVTGWG Enteropeptidase DNDIAMMHLEFKWNYTDYIOPICLPEENOVFPP- - - - - - - GRNCSIAGWG - - - - - - 2 - - - - - - Trypsin N- - - - - TASSGADYPDELOCLDAPVLSOAKCEASYPG-KITSNMFCWGFL a-Thrombin NLKETWTANVGKGOPSVLOVVNLPIVERPVCKDSTRI-RITDNMFCAGYK Enteropeptidase T- - - - - VVYOGTT-ANILOEADVPLLSNERCOOOMPEYNITENIMICAGYE - -3 - - Trypsin -EGGK--DSCOGDSGGPWVCNGO- - - - LQ- - - - - - GVVSWGDGCAQKNKP a-Thrombin PDEGKRGDACEGDSGGPFWMKSP- - - - FNNRWYQMGIWSWGEGCDRDGKY Enteropeptidase -EGGI- - DSCOGDSGGPLMCOENNRWFLA- - - - - - GVTSFGYKCALPNRP . 4 - - - - - Trypsin GVYTKWYNYWKWIKNTIAANS a-Thrombin GFYTHVFRLKKWIOKVIDOFGE Enteropeptidase GVYARWSRFTEWIQSFLH- - - - Fig. 2 Patent Application Publication Aug. 11, 2005 Sheet 3 of 18 US 2005/0175581 A1 Patent Application Publication Aug. 11, 2005 Sheet 4 of 18 US 2005/0175581 A1 sub IAHEYAOSV-- PY- - - - - - - - - - - - - - - GISO--IKAPALHSQGY - - - - - - - - - - - - - - - furin VAKRRAKRD-- VYOEPTDPKFPQQWYLSGVTQRDLNVKEAWAQGF- - - - - - - - - - - - - - - PC SK1 EKERSKRSALRDS- - - - - - - - - - - - - - - ALNL--FNDPMWNOOWYLODTRMTAALPKLDL PC SK5 NTHPCO- - - - - - - - - - - - - - - - - - - - - - - - SD--MNEGAWKRGY - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2 - - sub - - - - - - - - - - TGSNWKVAWIDSGDSSHPDL. --NVRGGAS- - FWPSETN- - - - - - - P- - - furin - - - - - - - - - - TGHGIWWSILDDGIEKNHPDLAGNYDPGAS--FDVNDOD- - - - - - - PDPO PC SK1 HVIPVWQKGITGKGVVITVLDDGLEWNHTDIYANYDPEASYDFNDNDHD- - - - - - - P- - - PC SK5 - - - - - - - - - - TGKNIWVTILDDGIERTHPDL. --MONYDA- -LASCDVNGNDLDPMP- - - as a or a lar a k - - - - - -3 - - - - - - - - - - - - - - - - - sub - - - - YO- - - - - DGSS- - -HGTHVAGTIA- -A-NNSIGWGVSPSASLYAVKVLDS - - - - furin PRYTOM- - - - - NDNR - - - HGTRCAGEVA- -AWANNGWCGVGWAYNARGGVRMLD - - - - - PC SK1 - - - - FPRYDPTNENK---HGTRCAGEIAMOAN-NHKCGV-GVAYNSKVGGIRMLDG - - - - PC SK5 - - - -RY - - - - - DASNENKHGTRCAGEVA- -AAANNSHCTWGIAFNAKIGGWRMLDGDWTD 4 - - - - - - - - - - - r a r r - air sub -TGSGOYSWIINGIE-WAISNNMDVINMSLG - - - - - - - - - GP - - GSTA - - - - - - LKT- - furin - - - - GEVTDAWEARS-LGLNPNHIHIYSASW - - - - - - - - - GPEDDGKVDGPARIAEE - - PC SK1 - IVTDAIEASSIGFN- - - - PGHVDIYSASWGPNDDGKTVEGP- --GRIA - - - - - - OKAFE PC SK5 MVEAKSVSFNPOHVHIYSASWGPDDDGKTVD- - - - - - - - - GPA - - PLT- - - - - - - - RQ- - - S - - - - - - - - - - - - 6- - - - - - - - - - - - - - 7- - - - - - - - - - - - - - - - - - - 8 - sub - -WWDKAWSSG - - - - - WVAAAAGNEGSS - - - - - - - GSTSTWGYPAKYPSTIAVGAV- - - furin --AFFRGVSOGRGGLGSIFVWASGNGGREHDSCNCDGYTNSI-YTLSISSATOFGNV- - - PC SK1 YGVKOGROGKG - - - - - SIFVWASGNGGRO - - - - - - - GDNCDCD- - - GYTDSIYTISI - - - PC SK5 --AFENGWRMGRRGLGSVFWWASGNGGRSKDHCSCDGYTNSI-YTISSSTAESGKKPWY - - - - 8-- - - - - - - - - - - - - - - - - - - - - 9 - - - - - - - - Sub --N- - - - - - SSNOR- - - - - - - - - - - - - - ASFSSAG-SELDVMAPGVSIOSTLPGGTYGAY furin --PWYSEACSSTLA- - - - - - - - - - - - - - TTYSSGNONEKOIVTTDLROKCT- - - - - - ESH PC SKl --S- - - - - - SASQOGLSPWYAEKCSSTLATSYSSG-DYTDQRITSADLHNDCT- - - - ETH PC SK5 LEE- - - - - - CSSTL - - - - - - - - - - - - - - ATTYSSG-ESYDKKI - - - - ITTDLRQRCTDNH - - - - - - - - - - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 11 - - - sub NGTSMATPHVAGAAALIL--SKHP- - TWTNAOVRDRLESTATY--LG-NSFYYGKGLINV furin TGTSASAPLAAGIIALTLEANKNL--TWRDMOHLVVOTSKPAH--LN-ADDWATNGWGRK PC SKl TGTSASAPLAAGIFALAL- -EANP--NLTWRDMQHLVVWTSEYDPLA-NNPGWKKNGAGL PC SK5 TGTSASAPMAAGIIALAL- -EANPFLTWRDVOHVIVRTSRAGH--LNANDWKTNAAGFKV - - - r Fig. 4 Patent Application Publication Aug. 11, 2005 Sheet 5 of 18 US 2005/0175581 A1 Fig.5 Patent Application Publication Aug. 11, 2005 Sheet 6 of 18 US 2005/0175581 A1 Peps. TLVDEOP- - - - LENYLDMEYFGTIGIGTPAODFTWWFDTGSSNLWVPSVYCSSL--ACTN Secr. EMWDN - - - - - - LRGKSGOGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFL- - - - - - Cath. PAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWI t - - - - 1 a a - - - - - 2- - Peps. HNRFNPEDSSTYQSTSETVSITYGTGSMTGILGYDTVOV- - - - - - - - - - - G - - - GISDTN Secr. HRYYOROLSSTYRDLRKGVYVPYTOGKWEGELGTDLVSI - - - - - - - - - - - PHGPNWTVRA Cath. HHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSODTVSWPCOSASSASALG---GVKVER - - - - - 3 - - - - - - - - - - - - - 4. - - - - - - - - - w x Peps. QIFGLSETEPGSFLYYAPFDGILGLAYPSIS--SSGATPVFDNIWNOGLVSQDLFSVYLS Sec. NIAAITESDK-FFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVP-NLFSLQLC Cath. OVFGEATKOPGITFIAAKFDGILGMAYPRIS--VNNVLPVFDNLMQQKLVDONIFSFYLS - - - - 5 - - - - it it - - - - - - 6 - Peps. ADD- - - - - - - - - - KS-- GSWWIFGGIDSSYYTGSLNWVPVTVEGYWOITVDSITMNGETI Secr. GAGFPLNOSEVLASV-- GGSMIIGGIDHSLYTGSLWYTPIRREWYYEWIIWRVEINGODL Cath. RDP- - - - - - - - - - DAOPGGEL.MLGGTDSKYYKGSLSYLNVTRKAYWOVHLDOVEVASGLT - - - - - - - - 7- - - - - - - - - - - - - - 8 - - - - - Peps. A- - CAEGC--OAIVDTGTSLLTGPTSPIANIOSDIGASENSD- - - - - - - - GDMVVSCSAI Secr. KMDCKEYNYDKSIVDSGTTNLRLPKKWFEAAVKSIKAASSTEKFPDGFWLGEOLV-CWOA Cath. L--CKEGC--EAIVDTGTSLMWGPWDEVRELOKAIGAVPLIO- - - - - - - - GEYMPCEKV - - - - - - - 9 - - - - - - t Peps. SSLPDIWFT - - - - - - - - - - - NGVCYPVPPSAYILOSEGS - - - - CISGFOGMNVP-TESG Sec. GTTPWNIFPVISLYLMGEWTNOSFRETILPOOYLRPVEDV - - - -ATSODDCYKFAISQSS Cath. STLPATLK - - - - - - - - - - - GGKGYKLSPEDYTLKVSOAGKTLCLSGFMGMDIP-PPSG - - - - - - - O - - - - s F - - - - - - - - - - - - - - 1. O - - Peps. ELWILGDWFIROYFTVFDRANNOVGLAPVA Secr. TGTWMGAVIMEGFYWWFDRARKRIGFAVSA Cath. PLWILGDVFIGRYYTVFDRDNNRWGFAEAA s Fig. 6 Patent Application Publication Aug. 11, 2005 Sheet 7 of 18 US 2005/0175581 A1 Fig. 7 Patent Application Publication Aug. 11, 2005 Sheet 8 of 18 US 2005/0175581 A1 Ol MLEADDQGCI EEOGVEDSAN EDSWDAKPDR SSFVPSLFSK KKKNWTMRSI KTTRDRVPTY 61 OYNMNFEKLG KCIIINNKNF DKVTGMGWRN GTDKDAEALF KCFRSLGFDV IWYNDCSCAK - - - - - - - - - - - - - - - 121 MODLLKKASE EDHTNAACFA CILLSHGEEN VIYGKDGVTP IKDLTAHFRG DRSKTLLEKP a - - - - 2- - - - - - - - - 181 KLFFIOACRG TELDDGIOAD SGPINDTDAN PRYKIPWEAD FLFAYSTVPG YYSWRSPGRG - - - - - 3 - - - - - - - - - - - - - - - - - - - 4 - - - - 241 SWFVQALCSI LEEHGKDLEI MOILTRVNDR VARHFESQSD DPHFHEKKQI PCVVSMLTKE - - - - - - - - - - - - - 5- - - - - - - - - - - - 301 LYFSQ Fig. 8 Patent Application Publication Aug. 11, 2005 Sheet 9 of 18 US 2005/0175581 A1 Protein Scaffod Protease A Protease B 1 2 3 Candidate SDR insertion sites Insertion of random SDRs into protein scaffold H- - - N-N-1 SpecificitySelection for increased NBE with intended specificity SDR1 SDR2 SDR3 Fig. 9 Patent Application Publication Aug. 11, 2005 Sheet 10 of 18 US 2005/0175581 A1 54 kDa 48 kDa 35 kDa 24 kDa Fig. 10 Patent Application Publication Aug. 11, 2005 Sheet 11 of 18 US 2005/0175581 A1 -- expressing cells - A - negative control O 1O 20 30 40 50 60 time (min) Fig. 11 Patent Application Publication Aug. 11, 2005 Sheet 13 of 18 US 2005/0175581 A1 trypsin SDR2 SDR1 & SDR2 Fig. 13 Patent Application Publication Aug. 11, 2005 Sheet 14 of 18 US 2005/0175581 A1 Fig. 14 Patent Application Publication Aug. 11, 2005 Sheet 15 of 18 US 2005/0175581 A1 4. O 3 5 22 O5 1 O live Cells dead Cells Varianti variantii variant iii Fig. 15 Patent Application Publication Aug. 11, 2005 Sheet 16 of 18 US 2005/0175581 A1 CNCN LOO 15 10 5 O 19 16 Patent Application Publication Aug. 11, 2005 Sheet 17 of 18 US 2005/0175581 A1 proteolytic digestion of TNF -ol-variantx -O- variantxi -A-variantxii -v-Trypsin
Load more

Recommended publications
  • Enzymes Handling/Processing
    Enzymes Handling/Processing 1 Identification of Petitioned Substance 2 3 This Technical Report addresses enzymes used in used in food processing (handling), which are 4 traditionally derived from various biological sources that include microorganisms (i.e., fungi and 5 bacteria), plants, and animals. Approximately 19 enzyme types are used in organic food processing, from 6 at least 72 different sources (e.g., strains of bacteria) (ETA, 2004). In this Technical Report, information is 7 provided about animal, microbial, and plant-derived enzymes generally, and more detailed information 8 is presented for at least one model enzyme in each group. 9 10 Enzymes Derived from Animal Sources: 11 Commonly used animal-derived enzymes include animal lipase, bovine liver catalase, egg white 12 lysozyme, pancreatin, pepsin, rennet, and trypsin. The model enzyme is rennet. Additional details are 13 also provided for egg white lysozyme. 14 15 Chemical Name: Trade Name: 16 Rennet (animal-derived) Rennet 17 18 Other Names: CAS Number: 19 Bovine rennet 9001-98-3 20 Rennin 25 21 Chymosin 26 Other Codes: 22 Prorennin 27 Enzyme Commission number: 3.4.23.4 23 Rennase 28 24 29 30 31 Chemical Name: CAS Number: 32 Peptidoglycan N-acetylmuramoylhydrolase 9001-63-2 33 34 Other Name: Other Codes: 35 Muramidase Enzyme Commission number: 3.2.1.17 36 37 Trade Name: 38 Egg white lysozyme 39 40 Enzymes Derived from Plant Sources: 41 Commonly used plant-derived enzymes include bromelain, papain, chinitase, plant-derived phytases, and 42 ficin. The model enzyme is bromelain.
    [Show full text]
  • The Sysco Cheese Product Catalog
    > the Sysco Cheese Product Catalog Sysco_Cheese_Cat.indd 1 7/27/12 10:55 AM 5 what’s inside! 4 More Cheese, Please! Sysco Cheese Brands 6 Cheese Trends and Facts Creamy and delicious, 8 Building Blocks... cheese fi ts in with meal of Natural Cheese segments during any Blocks and Shreds time of day – breakfast, Smoked Bacon & Cheddar Twice- Baked Potatoes brunch, lunch, hors d’oeuvres, dinner and 10 Natural Cheese from dessert. From a simple Mild to Sharp Cheddar, Monterey Jack garnish to the basis of and Swiss a rich sauce, cheese is an essential ingredient 9 10 12 A Guide to Great Italian Cheeses Soft, Semi-Soft and for many food service Hard Italian Cheeses operations. 14 Mozzarella... The Quintessential Italian Cheese Slices, shreds, loaves Harvest Vegetable French and wheels… with Bread Pizza such a multitude of 16 Cream Cheese Dreams culinary applications, 15 16 Flavors, Forms and Sizes the wide selection Blueberry Stuff ed French Toast of cheeses at Sysco 20 The Number One Cheese will provide endless on Burgers opportunities for Process Cheese Slices and Loaves menu innovation Stuff ed Burgers and increased 24 Hispanic-Style Cheeses perceived value. Queso Seguro, Special Melt and 20 Nacho Blend Easy Cheese Dip 25 What is Speciality Cheese? Brie, Muenster, Havarti and Fontina Baked Brie with Pecans 28 Firm/Hard Speciality Cheese Gruyère and Gouda 28 Gourmet White Mac & Cheese 30 Fresh and Blue Cheeses Feta, Goat Cheese, Blue Cheese and Gorgonzola Portofi no Salad with 2 Thyme Vinaigrette Sysco_Cheese_Cat.indd 2 7/27/12 10:56 AM welcome.
    [Show full text]
  • Substrate Specificities of Outer Membrane Proteases of the Omptin Family in Escherichia Coli, Salmonella Enterica, and Citrobacter Rodentium
    Substrate specificities of outer membrane proteases of the omptin family in Escherichia coli, Salmonella enterica, and Citrobacter rodentium Andrea Portt, McGill University, Montreal October 9th, 2010 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master’s in Microbiology © Andrea Portt 2010 Table of Contents LIST OF ABBREVIATIONS 3 ABSTRACT 6 ACKNOWLEDGEMENTS 7 CONTRIBUTIONS OF AUTHORS 8 LITERATURE REVIEW 9 2. OMPTINS 9 3. OMPTIN SUBSTRATES 13 A. ANTIMICROBIAL PEPTIDES 13 B. BLOOD CLOTTING PROTEINS AND EXTRACELLULAR MATRIX 14 C. COMPLEMENT 16 D. TROPOMYOSIN 17 4. EVOLUTION OF OMPTINS 17 5. OMPTIN REGULATION 20 6. OMPTINS OF PATHOGENIC ENTEROBACTEREACEAE 22 A. Y. PESTIS 22 B. S. ENTERICA 23 C. SHIGELLA 25 D. ATTACHING AND EFFACING BACTERIA 25 INTRODUCTION 28 MATERIALS AND METHODS 29 1. BACTERIAL GROWTH 29 2. BACTERIAL STRAINS AND CONSTRUCTION OF PLASMIDS 29 A. STRAINS 29 B. PLASMIDS 31 3. DISK INHIBITION ASSAYS 34 4. MINIMUM INHIBITORY CONCENTRATION DETERMINATIONS 34 5. PROTEOLYTIC CLEAVAGE OF AMPS BY CELLS EXPRESSING OMPTINS 34 6. OM DISRUPTION ASSAY WITH 1-N-PHENYLNAPHTHYLAMINE 35 7. DEGRADATION OF TROPOMYOSIN BY E. COLI AND C. RODENTIUM STRAINS EXPRESSING OMPTINS 35 8. REAL-TIME QUANTITATIVE PCR 35 9. PURIFICATION OF NATIVE CROP 35 10. EXPRESSION, PURIFICATION, AND REFOLDING OF HIS-PGTE AND HIS-CROP 36 A. EXPRESSION 36 B. PURIFICATION 36 C. REFOLDING 36 11. CLEAVAGE OF C2 FRET SUBSTRATE BY WHOLE CELLS OR PURIFIED OMPTINS 37 A. WHOLE CELLS 37 B. PURIFIED OMPTINS 37 1 RESULTS 38 1. GROWTH INHIBITION OF E. COLI AND C. RODENTIUM STRAINS EXPRESSING OMPTINS BY C18G.
    [Show full text]
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • Progress in the Field of Aspartic Proteinases in Cheese Manufacturing
    Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin, Peter Dekker To cite this version: Sirma Yegin, Peter Dekker. Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering. Dairy Science & Technology, EDP sciences/Springer, 2013, 93 (6), pp.565-594. 10.1007/s13594-013-0137-2. hal-01201447 HAL Id: hal-01201447 https://hal.archives-ouvertes.fr/hal-01201447 Submitted on 17 Sep 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Dairy Sci. & Technol. (2013) 93:565–594 DOI 10.1007/s13594-013-0137-2 REVIEW PAPER Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin & Peter Dekker Received: 25 February 2013 /Revised: 16 May 2013 /Accepted: 21 May 2013 / Published online: 27 June 2013 # INRA and Springer-Verlag France 2013 Abstract Aspartic proteinases are an important class of proteinases which are widely used as milk-coagulating agents in industrial cheese production. They are available from a wide range of sources including mammals, plants, and microorganisms.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Of 3 Enzymatic Assay of RENNIN (EC 3.4.23.4) PRINCIPLE
    Enzymatic Assay of RENNIN (EC 3.4.23.4) PRINCIPLE: Rennin 1 Milk > Clotted Milk CONDITIONS: T = 30°C METHOD: Clotting time REAGENTS: A. 1 M Calcium Chloride Solution (Prepare 5 ml in deionized water using Calcium Chloride, Dihydrate, Sigma Prod. No. C-3881.) B. 10.4% (w/v) Milk Solution with 10 mM Calcium Chloride (Milk) (Prepare by dissolving 20.9 g of Carnation Instant Nonfat Dry Milk Powder in 200 ml of deionized water or use skimmed cow's milk. Then add 2 ml of Reagent A.) C. 0.1% (w/v) Rennet Standard Solution (Rennet Std) (Prepare 10 ml in deionized water using Rennet, Sigma Prod. No. R-3376.) D. Rennin Enzyme Solution (Rennin) (Immediately before use, prepare a solution containing 0.01 - 0.05 mg/ml of Rennin in cold deionized water. Dilute accordingly so that the clotting time is 0.75 - 1.5 times that of Reagent C.) VEMILK01 Page 1 of 3 Revised: 08/29/97 Enzymatic Assay of RENNIN (EC 3.4.23.4) PROCEDURE: Step 1: Pipette (in milliliters) the following reagents into a 50 ml Erlenmeyer flask: Control Reagent B (Milk) 10.00 Incubate at 30°C in a water bath for 45 minutes. At t0 add: Reagent C (Rennet Std) 1.00 Swirl gently (Erlenmeyer flask) at 30°C in a water bath. Stop timing and swirling when a white-translucent semi- liquified film appears on the side of the flask above the milk. This is t1. After t1, the milk will continue to congeal. Step 2: Pipette (in milliliters) the following reagents into a suitable test tube.
    [Show full text]
  • Proteolytic Enzymes in Grass Pollen and Their Relationship to Allergenic Proteins
    Proteolytic Enzymes in Grass Pollen and their Relationship to Allergenic Proteins By Rohit G. Saldanha A thesis submitted in fulfilment of the requirements for the degree of Masters by Research Faculty of Medicine The University of New South Wales March 2005 TABLE OF CONTENTS TABLE OF CONTENTS 1 LIST OF FIGURES 6 LIST OF TABLES 8 LIST OF TABLES 8 ABBREVIATIONS 8 ACKNOWLEDGEMENTS 11 PUBLISHED WORK FROM THIS THESIS 12 ABSTRACT 13 1. ASTHMA AND SENSITISATION IN ALLERGIC DISEASES 14 1.1 Defining Asthma and its Clinical Presentation 14 1.2 Inflammatory Responses in Asthma 15 1.2.1 The Early Phase Response 15 1.2.2 The Late Phase Reaction 16 1.3 Effects of Airway Inflammation 16 1.3.1 Respiratory Epithelium 16 1.3.2 Airway Remodelling 17 1.4 Classification of Asthma 18 1.4.1 Extrinsic Asthma 19 1.4.2 Intrinsic Asthma 19 1.5 Prevalence of Asthma 20 1.6 Immunological Sensitisation 22 1.7 Antigen Presentation and development of T cell Responses. 22 1.8 Factors Influencing T cell Activation Responses 25 1.8.1 Co-Stimulatory Interactions 25 1.8.2 Cognate Cellular Interactions 26 1.8.3 Soluble Pro-inflammatory Factors 26 1.9 Intracellular Signalling Mechanisms Regulating T cell Differentiation 30 2 POLLEN ALLERGENS AND THEIR RELATIONSHIP TO PROTEOLYTIC ENZYMES 33 1 2.1 The Role of Pollen Allergens in Asthma 33 2.2 Environmental Factors influencing Pollen Exposure 33 2.3 Classification of Pollen Sources 35 2.3.1 Taxonomy of Pollen Sources 35 2.3.2 Cross-Reactivity between different Pollen Allergens 40 2.4 Classification of Pollen Allergens 41 2.4.1
    [Show full text]
  • Structure Prediction of Outer Membrane Protease Protein of Salmonella Typhimurium Using Computational Techniques
    INT. J. BIOAUTOMATION, 2016, 20(1), 5-18 Structure Prediction of Outer Membrane Protease Protein of Salmonella typhimurium Using Computational Techniques Rozina Tabassum*, Muhammad Haseeb, Sahar Fazal Department of Bioinformatics and Biosciences Mohammad Ali Jinnah University Islamabad, Pakistan E-mails: [email protected], [email protected], [email protected] *Corresponding author Received: April 04, 2015 Accepted: November 16, 2015 Published: March 31, 2016 Abstract: Salmonella typhimurium, a facultative gram-negative intracellular pathogen belonging to family Enterobacteriaceae, is the most frequent cause of human gastroenteritis worldwide. PgtE gene product,outer membrane protease emerges important in the intracellular phases of salmonellosis. The pgtE gene product of S. typhimurium was predicted to be capable of proteolyzing T7 RNA polymerase and localize in the outer membrane of these gram negative bacteria. PgtE product of S. enterica and OmpT of E. coli, having high sequence similarity have been revealed to degrade macrophages, causing salmonellosis and other diseases. The three-dimensional structure of the protein was not available through Protein Data Bank (PDB) creating lack of structural information about E protein. In our study, by performing Comparative model building, the three dimensional structure of outer membrane protease protein was generated using the backbone of the crystal structure of Pla of Yersinia pestis, retrieved from PDB, with MODELLER (9v8). Quality of the model was assessed by validation tool PROCHECK, web servers like ERRAT and ProSA are used to certify the reliability of the predicted model. This information might offer clues for better understanding of E protein and consequently for developmet of better therapeutic treatment against pathogenic role of this protein in salmonellosis and other diseases.
    [Show full text]
  • Apolipoprotein(A) Secretion Is Modulated by Sortilin, Proprotein Convertase Subtilisin/Kexin Type 9, and Microsomal Triglyceride Transfer Protein
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 6-24-2019 10:30 AM Apolipoprotein(a) Secretion is Modulated by Sortilin, Proprotein Convertase Subtilisin/Kexin Type 9, and Microsomal Triglyceride Transfer Protein Justin Clark The University of Western Ontario Supervisor Koschinsky, Marlys L. Robarts Research Institute Graduate Program in Physiology and Pharmacology A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Science © Justin Clark 2019 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Cardiovascular Diseases Commons Recommended Citation Clark, Justin, "Apolipoprotein(a) Secretion is Modulated by Sortilin, Proprotein Convertase Subtilisin/Kexin Type 9, and Microsomal Triglyceride Transfer Protein" (2019). Electronic Thesis and Dissertation Repository. 6310. https://ir.lib.uwo.ca/etd/6310 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Elevated plasma lipoprotein(a) (Lp(a)) levels are a causal risk factor for cardiovascular disease (CVD), but development of specific Lp(a) lowering therapeutics has been hindered by insufficient understanding of Lp(a) biology. For example, the location of the noncovalent interaction that precedes the extracellular disulfide linkage between apolipoprotein(a) (apo(a)) and apolipoprotein B-100 (apoB-100) in Lp(a) biosynthesis is unclear. In this study we modulated known intracellular regulators of apoB-100 production and then assessed apo(a) secretion from human HepG2 cells expressing 17-kringle (17K) apo(a) isoform variants using pulse-chase analysis.
    [Show full text]
  • N-Glycosylation in the Protease Domain of Trypsin-Like Serine Proteases Mediates Calnexin-Assisted Protein Folding
    RESEARCH ARTICLE N-glycosylation in the protease domain of trypsin-like serine proteases mediates calnexin-assisted protein folding Hao Wang1,2, Shuo Li1, Juejin Wang1†, Shenghan Chen1‡, Xue-Long Sun1,2,3,4, Qingyu Wu1,2,5* 1Molecular Cardiology, Cleveland Clinic, Cleveland, United States; 2Department of Chemistry, Cleveland State University, Cleveland, United States; 3Chemical and Biomedical Engineering, Cleveland State University, Cleveland, United States; 4Center for Gene Regulation of Health and Disease, Cleveland State University, Cleveland, United States; 5Cyrus Tang Hematology Center, State Key Laboratory of Radiation Medicine and Prevention, Soochow University, Suzhou, China Abstract Trypsin-like serine proteases are essential in physiological processes. Studies have shown that N-glycans are important for serine protease expression and secretion, but the underlying mechanisms are poorly understood. Here, we report a common mechanism of N-glycosylation in the protease domains of corin, enteropeptidase and prothrombin in calnexin- mediated glycoprotein folding and extracellular expression. This mechanism, which is independent *For correspondence: of calreticulin and operates in a domain-autonomous manner, involves two steps: direct calnexin [email protected] binding to target proteins and subsequent calnexin binding to monoglucosylated N-glycans. Elimination of N-glycosylation sites in the protease domains of corin, enteropeptidase and Present address: †Department prothrombin inhibits corin and enteropeptidase cell surface expression and prothrombin secretion of Physiology, Nanjing Medical in transfected HEK293 cells. Similarly, knocking down calnexin expression in cultured University, Nanjing, China; ‡Human Aging Research cardiomyocytes and hepatocytes reduced corin cell surface expression and prothrombin secretion, Institute, School of Life Sciences, respectively. Our results suggest that this may be a general mechanism in the trypsin-like serine Nanchang University, Nanchang, proteases with N-glycosylation sites in their protease domains.
    [Show full text]
  • Current Status and Perspectives of Protease Inhibitors and Their
    Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy Magdalena Rudzińska, Cenk Daglioglu, Lyudmila Savvateeva, Fatma Necmiye Kaci, Rodolphe Antoine, Andrey Zamyatnin Jr To cite this version: Magdalena Rudzińska, Cenk Daglioglu, Lyudmila Savvateeva, Fatma Necmiye Kaci, Rodolphe An- toine, et al.. Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy. Drug Design, Development and Therapy, Dove Medical Press, 2021, 15, pp.9-20. 10.2147/DDDT.S285852. hal-03128092 HAL Id: hal-03128092 https://hal.archives-ouvertes.fr/hal-03128092 Submitted on 26 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article PERSPECTIVES Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy This article was published in the following Dove Press journal: Drug Design, Development and Therapy Magdalena Rudzińska 1 Abstract: In cancer treatments, many natural and synthetic products have been examined; Cenk Daglioglu 2 among them, protease inhibitors are promising candidates for anti-cancer agents.
    [Show full text]